Ally Bridge Group (Ny) LLC Relmada Therapeutics, Inc. Transaction History
Ally Bridge Group (Ny) LLC
- $141 Million
- Q3 2024
Shares
1 transactions
Others Institutions Holding RLMD
# of Institutions
78Shares Held
11.5MCall Options Held
229KPut Options Held
138K-
Franklin Resources Inc San Mateo, CA1.3MShares$507,8380.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.26MShares$490,1140.0% of portfolio
-
Acadian Asset Management LLC Boston, MA1.19MShares$462,7160.01% of portfolio
-
Palo Alto Investors LP Palo Alto, CA732KShares$285,6360.33% of portfolio
-
Deep Track Capital, LP Greenwich, CT675KShares$263,1840.08% of portfolio
About RELMADA THERAPEUTICS, INC.
- Ticker RLMD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,608,500
- Market Cap $11.2M
- Description
- Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...